Products

Paclitaxel Injection 60mg /10ml GMP Certificated Western Medicine

China Paclitaxel Injection 60mg/10ml GMP Certificated Western Medicine, Find details about China Taxinol, Liquid Injection from Paclitaxel Injection 60mg/10ml GMP Certificated Western Medicine

Pharmaceutical Technology
Chemical Synthesis
Standard
Bp/USP
Storage
Protect From Light.
Packaging
1 Ampoules/Box
Trademark
OEM
Specification
Paclitaxel 60mg/10ml
Origin
China
Pharmaceutical Technology
Chemical Synthesis
Standard
Bp/USP
Storage
Protect From Light.
Packaging
1 Ampoules/Box
Trademark
OEM
Specification
Paclitaxel 60mg/10ml
Origin
China
Product name: Paclitaxel Injection
Category: Liquid Injection 
Package: 60mg/10ml/ampoule/box
Brand: OEM/GMP 
Packaging Details: As usual, we also can make as your requirement. 
Function indications:
This product is used for the first-line and second-line treatment of ovarian cancer, breast cancer and NSCLC. Head and neck cancer, esophageal cancer, seminoma, recurrent non-Hodgkin's lymphoma, etc.
Adverse reactions:
1. Anaphylaxis: the incidence was 39%, and the incidence of severe anaphylaxis was 2%. Most of them are type I allergic reactions, such as bronchospasm dyspnea, urticaria and hypotension. Almost all reactions took place in the first 10 minutes after administration.
2. Myelosuppression: it is a major dose limiting toxicity, characterized by neutropenia and rare thrombocytopenia, which generally occurs 8-10 days after treatment. The incidence of severe neutrophil and thrombocytopenia was 47% and 5%, respectively. Anemia is more common.
3. Neurotoxicity: the incidence of peripheral neuropathy was 62%, the most common manifestations were mild numbness and sensory abnormality, and the incidence of severe neurotoxicity was 6%.
4. Cardiovascular toxicity: it can have hypotension and asymptomatic short-term bradycardia. Muscle and joint pain: the incidence is 55%, which occurs in the joints of limbs. The incidence and severity are dose-dependent.
5. Gastrointestinal reaction: the incidence of nausea, vomiting, diarrhea and mucositis were 59%, 43% and 39% respectively, generally mild and moderate.
6. Hepatotoxicity: alt, AST and AKP increased.
7. Hair loss: the incidence was 80%.
8. Local reaction: inflammation in the vein of drug infusion and local drug extravasation.
Taboo:
Allergic to polyoxyethyl castor oil. It is prohibited for those with neutrophils lower than 1500 / mm.
matters needing attention:
Before treatment, dexamethasone, diphenhydramine and H2 receptor antagonists were used for pretreatment. Undiluted concentrated solution shall not contact PVC plastic instruments or equipment, and shall not be intravenous drip. The diluted solution shall be stored in bottles or plastic bags, and drip with PVC dosing equipment. During the administration, attention should be paid to whether there are allergic reactions and changes in life characteristics.
Drug interactions:
Pharmacokinetic data showed that the clearance rate of cisplatin was reduced by about 30%, and the bone marrow toxicity was serious. At the same time, ketoconazole can affect the metabolism of the product.
Pharmacological action:
This product is a new type of anti tubulin drug, which can inhibit the depolymerization by promoting the polymerization of tubulin, keep the stability of tubulin and inhibit the mitosis of cells. In vitro experiments show that paclitaxel has a significant radiosensitization effect, which may cause the cells to stop at G2 and M stages sensitive to radiotherapy.
Paclitaxel Injection 60mg/10ml GMP Certificated Western Medicine
 

You Might Also Like